Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer
Lorenz, I.; Mechl, Z.
Neoplasma 32(1): 119-124
1985
ISSN/ISBN: 0028-2685 PMID: 3157070 Document Number: 243799
A comparison of efficacies of medroxyprogesterone acetate (MPA) and the antiestrogen tamoxifen (TX) in the therapy for advanced breast cancer in patients who had already previously been intensely treated showed that, as to the objective remissions, the two drugs can be looked upon as equivalent. Nevertheless, with MPA a better analgetic and anabolic effect--a marked improvement in the performance status (Karnofsky index)--was achieved.
Document emailed within 1 workday
Related Documents
Sica, G.; Iacopino, F.; Marini, L.; Robustelli della Cuna, G. 1992: Antiproliferative effect of leuprorelin acetate, alone or combined with tamoxifen or medroxyprogesterone acetate, on human breast cancer cell lines Clinical Therapeutics 14 Suppl A: 87-96Sonoo, H.; Senoo, T.; Nishiki, M.; Morimoto, T.; Takashima, S. 1996: Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(4): 447-454
Sturm, G.; Antal, E.; Schmidt Rhode, P.; Bauer, T.; Schulz K D. 1986: Medroxyprogesterone acetate and immunoreactive medroxyprogesterone acetate metabolites measured by two different selective radioimmunoassay antibodies in medroxyprogesterone acetate treated breast cancer patients Anticancer Research 6(3 Part A): 362
Kihara, M.; Kontani, K.; Yamauchi, A.; Yokomise, H. 2005: Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(5): 683-686
Sica, G.; Lama, G.; Iacopino, F.; Angelucći, C.; Della Cuna, G.R.; Marchetti, P. 1991: Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells Anticancer Research 11(6): 2099-2102
Nomura, Y.; Tashiro, H.; Hisamatsu, K.; Toi, M. 1988: Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(3): 513-518
Pannuti, F.; Di Marco, A.R.; Martoni, A.; Fruet, F.; Strocchi, E.; Burroni, P.; Marraro, D. 1982: Medroxyprogesterone acetate (MAP) in high doses in the treatment of breast cancer in advanced stages Minerva Ginecologica 34(11): 977-979
Møller, K.A.; Andersen, A.P. 1981: Peroral administration of medroxyprogesterone acetate (MPA) in advanced cancer of the breast. A preliminary report Acta obstetricia et gynecologica Scandinavica. Supplement 101: 47-48
Powles, T.J.; Gordon, C.; Coombes, R.C. 1982: Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone Cancer Research 42(8 Suppl): 3458s-3460s
Guarnieri, A.; Tucci, E.; D'Aniello, C.; Carli, A.; Mariani, L.; De Stefano, A.; Nardi, P. 1984: Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 3(5): 320-323
Mitsuyama, S.; Kuroda, Y.; Ohsato, K.; Nakamura, Y.; Murakami, F.; Nishikata, F.; Ikeda, S.; Egami, T.; Mori, A.; Ohe, H. 1996: Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(9): 1153-1160
Chiesa, M.Dalla.; Passalacqua, R.; Michiara, M.; Franciosi, V.; Di Costanzo, F.; Bisagni, G.; Camisa, R.; Buti, S.; Tomasello, G.; Cocconi, G. 2007: Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial Acta Bio-Medica: Atenei Parmensis 78(3): 204-209
Bonomi, P.; Gale, M.; Von Roenn, J.; Anderson, K.; Johnson, P.; Wolter, J.; Economou, S. 1988: Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen Seminars in Oncology 15(2 Suppl 1: 26-33
Klaassen, D.J.; Rapp, E.F.; Hirte, W.E. 1976: Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women Cancer Treatment Reports 60(3): 251-253
Takatsuka, Y.; Katoh, T.; Tsumura, I.; Kobayakawa, K.; Kawahara, T. 1992: Successful treatment of disseminated breast cancer with combination therapy of 5'-deoxy-5'-fluorouridine (5'-DFUR), medroxyprogesterone acetate (MPA) and cyclophosphamide (CPA) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(1): 107-110
Novoa Vargas, A.; Font López, K.C.; Amador, D.D. 2011: Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer Ginecologia y Obstetricia de Mexico 79(9): 553-557
Zia, Y.; Tang, J.H.; Chinula, L.; Tegha, G.; Stanczyk, F.Z.; Kourtis, A.P. 2019: Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi Contraception 100(5): 402-405
Johnson, P.A.; Muss, H.; Bonomi, P.; Von Roenn, J.; Wolter, J.; Paschold, E.; Black, W.; Cooper, M. 1988: Megestrol acetate as primary hormonal therapy for advanced breast cancer Seminars in Oncology 15(2 Suppl 1: 34-37
Izumi, M.; Iino, Y.; Yokoe, T.; Inoue, T.; Yamada, T.; Kobayashi, I.; Andoh, T.; Yokota, T.; Iijima, T.; Morishita, Y. 1994: Advanced breast cancer with remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy: a case report Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(2): 265-268
Yoshida, M.; Saji, S.; Takagi, H.; Takeuchi, S.; Tsuda, H.; Nimura, Y.; Mizumoto, R.; Miyazaki, I.; Kobayashi, S.; Noguchi, M. 1993: A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. the Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(15): 2325-2333